Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer - - BioPharm International

ADVERTISEMENT

Waters Introduces Ion Mobility-Enhanced Research Mass Spectrometer


Waters Corporation introduced the Waters SYNAPT G2-Si Mass Spectrometer, which integrates a third dimension of resolution and separation power into a new suite of untargeted and targeted LC/MS/MS workflows. The system combines the power of Travelling Wave (T-Wave) Ion Mobility Separations with new data acquisition and informatics technologies, and collision cross section (CCS) measurements.

The mass spectrometer is the first MS system to elevate CCS alongside retention time and mass to charge ratio (m/z) as a robust, reliable identification parameter in library-based screening, according to a Waters press statement. The collision cross section of a molecule is an important distinguishing feature that is directly related to its chemical structure and three-dimensional conformation in the gas-phase. Like molecular mass, this additional orthogonal property of a molecule (through the use of high-efficiency T-wave ion mobility technology) gives scientists increased coverage and clarity for profiling mixtures or gaining additional measurements with which they can investigate chemical structures or better confirm a molecule's identity.

The system offers maximized time-of-flight (Tof) duty cycle and effective sensitivity, of up to 10x in MS/MS mode, for targeted discovery and quantitation. Improved LC/MS/MS efficiency includes a 40% improvement in the numbers of proteins identified from an E. coli sample and the identification of more than 2,000 proteins from a HeLa sample. A 2.5KHz solid-state laser combines with new software for improved spatial resolution (down to 15 microns) for cleaner mass spectral data and greater image throughput when performing experiments with MALDI imaging and T-wave ion mobility.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here